The positive rates of hepatitis B surface antibody in youth after booster vaccination: a 4-year follow-up study with large sample
Hepatitis B virus (HBV) infection is still a public issue in the world. Hepatitis B vaccination is widely used as an effective measure to prevent HBV infection. This large-sample study aimed to evaluate the positive rates of hepatitis B surface antibody (anti-HBs) in youth after booster vaccination....
Saved in:
| Published in | Bioscience reports Vol. 41; no. 9; p. 1 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
Portland Press Ltd The Biochemical Society
30.09.2021
Portland Press Ltd |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Hepatitis B virus (HBV) infection is still a public issue in the world. Hepatitis B vaccination is widely used as an effective measure to prevent HBV infection. This large-sample study aimed to evaluate the positive rates of hepatitis B surface antibody (anti-HBs) in youth after booster vaccination.
A total of 37788 participants were divided into two groups according to the baseline levels of anti-HBs before booster vaccination: the negative group (anti-HBs(-)) and the positive group (anti-HBs(+)). Participants were tested for anti-HBs levels after receiving a booster vaccine at 1 and 4 years.
The positive rates of anti-HBs were 34.50%, 73.80% and 67.32% before booster vaccination at 1 and 4 years after vaccination, respectively. At 4 years after the booster vaccination, the positive rates of 13-18 years were 47.54%, which was the lowest level among all youth age groups. In the anti-HBs(-) group, the positive conversion rates of anti-HBs were 74.62% at 1 year after receiving a booster vaccine, and 67.66% at 4 years after vaccination. In the anti-HBs(+) group, the positive maintenance rates of anti-HBs were 70.16% after 1 year, and 66.66% after 4 years. Compared with the baseline anti-HBs (+) group, the positive rates of the baseline anti-HBs(-) group were higher at 1 and 4 years after receiving the booster vaccine.
The positive rates of anti-HBs declined over time, especially the positive maintenance rates were the lowest at age of 13-18 years. |
|---|---|
| AbstractList | Abstract
Background: Hepatitis B virus (HBV) infection is still a public issue in the world. Hepatitis B vaccination is widely used as an effective measure to prevent HBV infection. This large-sample study aimed to evaluate the positive rates of hepatitis B surface antibody (anti-HBs) in youth after booster vaccination.
Methods: A total of 37788 participants were divided into two groups according to the baseline levels of anti-HBs before booster vaccination: the negative group (anti-HBs(−)) and the positive group (anti-HBs(+)). Participants were tested for anti-HBs levels after receiving a booster vaccine at 1 and 4 years.
Results: The positive rates of anti-HBs were 34.50%, 73.80% and 67.32% before booster vaccination at 1 and 4 years after vaccination, respectively. At 4 years after the booster vaccination, the positive rates of 13–18 years were 47.54%, which was the lowest level among all youth age groups. In the anti-HBs(−) group, the positive conversion rates of anti-HBs were 74.62% at 1 year after receiving a booster vaccine, and 67.66% at 4 years after vaccination. In the anti-HBs(+) group, the positive maintenance rates of anti-HBs were 70.16% after 1 year, and 66.66% after 4 years. Compared with the baseline anti-HBs (+) group, the positive rates of the baseline anti-HBs(−) group were higher at 1 and 4 years after receiving the booster vaccine.
Conclusion: The positive rates of anti-HBs declined over time, especially the positive maintenance rates were the lowest at age of 13–18 years. Hepatitis B virus (HBV) infection is still a public issue in the world. Hepatitis B vaccination is widely used as an effective measure to prevent HBV infection. This large-sample study aimed to evaluate the positive rates of hepatitis B surface antibody (anti-HBs) in youth after booster vaccination. A total of 37788 participants were divided into two groups according to the baseline levels of anti-HBs before booster vaccination: the negative group (anti-HBs(-)) and the positive group (anti-HBs(+)). Participants were tested for anti-HBs levels after receiving a booster vaccine at 1 and 4 years. The positive rates of anti-HBs were 34.50%, 73.80% and 67.32% before booster vaccination at 1 and 4 years after vaccination, respectively. At 4 years after the booster vaccination, the positive rates of 13-18 years were 47.54%, which was the lowest level among all youth age groups. In the anti-HBs(-) group, the positive conversion rates of anti-HBs were 74.62% at 1 year after receiving a booster vaccine, and 67.66% at 4 years after vaccination. In the anti-HBs(+) group, the positive maintenance rates of anti-HBs were 70.16% after 1 year, and 66.66% after 4 years. Compared with the baseline anti-HBs (+) group, the positive rates of the baseline anti-HBs(-) group were higher at 1 and 4 years after receiving the booster vaccine. The positive rates of anti-HBs declined over time, especially the positive maintenance rates were the lowest at age of 13-18 years. BACKGROUNDHepatitis B virus (HBV) infection is still a public issue in the world. Hepatitis B vaccination is widely used as an effective measure to prevent HBV infection. This large-sample study aimed to evaluate the positive rates of hepatitis B surface antibody (anti-HBs) in youth after booster vaccination. METHODSA total of 37788 participants were divided into two groups according to the baseline levels of anti-HBs before booster vaccination: the negative group (anti-HBs(-)) and the positive group (anti-HBs(+)). Participants were tested for anti-HBs levels after receiving a booster vaccine at 1 and 4 years. RESULTSThe positive rates of anti-HBs were 34.50%, 73.80% and 67.32% before booster vaccination at 1 and 4 years after vaccination, respectively. At 4 years after the booster vaccination, the positive rates of 13-18 years were 47.54%, which was the lowest level among all youth age groups. In the anti-HBs(-) group, the positive conversion rates of anti-HBs were 74.62% at 1 year after receiving a booster vaccine, and 67.66% at 4 years after vaccination. In the anti-HBs(+) group, the positive maintenance rates of anti-HBs were 70.16% after 1 year, and 66.66% after 4 years. Compared with the baseline anti-HBs (+) group, the positive rates of the baseline anti-HBs(-) group were higher at 1 and 4 years after receiving the booster vaccine. CONCLUSIONThe positive rates of anti-HBs declined over time, especially the positive maintenance rates were the lowest at age of 13-18 years. Background: Hepatitis B virus (HBV) infection is still a public issue in the world. Hepatitis B vaccination is widely used as an effective measure to prevent HBV infection. This large-sample study aimed to evaluate the positive rates of hepatitis B surface antibody (anti-HBs) in youth after booster vaccination. Methods: A total of 37788 participants were divided into two groups according to the baseline levels of anti-HBs before booster vaccination: the negative group (anti-HBs(−)) and the positive group (anti-HBs(+)). Participants were tested for anti-HBs levels after receiving a booster vaccine at 1 and 4 years. Results: The positive rates of anti-HBs were 34.50%, 73.80% and 67.32% before booster vaccination at 1 and 4 years after vaccination, respectively. At 4 years after the booster vaccination, the positive rates of 13–18 years were 47.54%, which was the lowest level among all youth age groups. In the anti-HBs(−) group, the positive conversion rates of anti-HBs were 74.62% at 1 year after receiving a booster vaccine, and 67.66% at 4 years after vaccination. In the anti-HBs(+) group, the positive maintenance rates of anti-HBs were 70.16% after 1 year, and 66.66% after 4 years. Compared with the baseline anti-HBs (+) group, the positive rates of the baseline anti-HBs(−) group were higher at 1 and 4 years after receiving the booster vaccine. Conclusion: The positive rates of anti-HBs declined over time, especially the positive maintenance rates were the lowest at age of 13–18 years. Background: Hepatitis B virus (HBV) infection is still a public issue in the world. Hepatitis B vaccination is widely used as an effective measure to prevent HBV infection. This large-sample study aimed to evaluate the positive rates of hepatitis B surface antibody (anti-HBs) in youth after booster vaccination. Methods: A total of 37788 participants were divided into two groups according to the baseline levels of anti-HBs before booster vaccination: the negative group (anti-HBs(−)) and the positive group (anti-HBs(+)). Participants were tested for anti-HBs levels after receiving a booster vaccine at 1 and 4 years. Results: The positive rates of anti-HBs were 34.50%, 73.80% and 67.32% before booster vaccination at 1 and 4 years after vaccination, respectively. At 4 years after the booster vaccination, the positive rates of 13–18 years were 47.54%, which was the lowest level among all youth age groups. In the anti-HBs(−) group, the positive conversion rates of anti-HBs were 74.62% at 1 year after receiving a booster vaccine, and 67.66% at 4 years after vaccination. In the anti-HBs(+) group, the positive maintenance rates of anti-HBs were 70.16% after 1 year, and 66.66% after 4 years. Compared with the baseline anti-HBs (+) group, the positive rates of the baseline anti-HBs(−) group were higher at 1 and 4 years after receiving the booster vaccine. Conclusion: The positive rates of anti-HBs declined over time, especially the positive maintenance rates were the lowest at age of 13–18 years. |
| Author | Zhu, Xia Du, Ling-Yao Zhang, Xuan Wang, Juan Ji, Yu-Lin Tang, Hong Wang, Ming |
| AuthorAffiliation | 2 Respiratory and Critical Care Medicine Department, West China Hospital of Sichuan University, Chengdu 610041, P.R. China 1 Center of Infectious Diseases, West China Hospital of Sichuan University, No.37 Guo Xue Xiang, Chengdu 610041, P.R. China |
| AuthorAffiliation_xml | – name: 1 Center of Infectious Diseases, West China Hospital of Sichuan University, No.37 Guo Xue Xiang, Chengdu 610041, P.R. China – name: 2 Respiratory and Critical Care Medicine Department, West China Hospital of Sichuan University, Chengdu 610041, P.R. China |
| Author_xml | – sequence: 1 givenname: Xia surname: Zhu fullname: Zhu, Xia organization: Center of Infectious Diseases, West China Hospital of Sichuan University, No.37 Guo Xue Xiang, Chengdu 610041, P.R. China – sequence: 2 givenname: Juan surname: Wang fullname: Wang, Juan organization: Center of Infectious Diseases, West China Hospital of Sichuan University, No.37 Guo Xue Xiang, Chengdu 610041, P.R. China – sequence: 3 givenname: Ming surname: Wang fullname: Wang, Ming organization: Center of Infectious Diseases, West China Hospital of Sichuan University, No.37 Guo Xue Xiang, Chengdu 610041, P.R. China – sequence: 4 givenname: Ling-Yao surname: Du fullname: Du, Ling-Yao organization: Center of Infectious Diseases, West China Hospital of Sichuan University, No.37 Guo Xue Xiang, Chengdu 610041, P.R. China – sequence: 5 givenname: Yu-Lin surname: Ji fullname: Ji, Yu-Lin organization: Respiratory and Critical Care Medicine Department, West China Hospital of Sichuan University, Chengdu 610041, P.R. China – sequence: 6 givenname: Xuan surname: Zhang fullname: Zhang, Xuan organization: Respiratory and Critical Care Medicine Department, West China Hospital of Sichuan University, Chengdu 610041, P.R. China – sequence: 7 givenname: Hong orcidid: 0000-0003-3912-2067 surname: Tang fullname: Tang, Hong organization: Center of Infectious Diseases, West China Hospital of Sichuan University, No.37 Guo Xue Xiang, Chengdu 610041, P.R. China |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34151935$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kstrFTEUxoNU7O3VlXsJuBFkNK-Zybgo2FIfUBC0rsOZzElvytxkTGZuuUv_86a0lurC1YHz_b7DeR2RgxADEvKSs3ecKfH-5Md3wQRnXIsnZMXrVlaqk_UBWTGuVKVVIw_JUc5XjLEiqGfkUCpe88KsyO-LDdIpZj_7HdIEM2YaHd3gBHPJZXpC85IcWKQQZt_HYU99oPu4zBsKbsZE-xjzbdyBtT4UWwwfKFBV7RESdXEc43W1TDTPSzFf-2IcIV0izbCdRnxOnjoYM764j2vy89PZxemX6vzb56-nH88rK7XmFQ4tH4TCoXOSWQu27zhvtG4kWgYM6w4ctK5mXLCis57rvqh1j4MTiFauyfFd3WnptzhYDHOC0UzJbyHtTQRv_laC35jLuDO6LEuWJa7Jm_sCKf5aMM9m67PFcYSAcclG1Eq2THZNV9DX_6BXcUmhjGckk5J1QtbN_yjRyVYzJWVbqLd3lE0x54TuoWXOzO0DmEcPUOhXj6d8YP9cXN4A5ReuhQ |
| CitedBy_id | crossref_primary_10_3748_wjg_v29_i19_3003 |
| Cites_doi | 10.1080/21645515.2016.1260794 10.1080/21645515.2018.1426419 10.1016/j.vaccine.2007.09.013 10.1016/S1473-3099(19)30582-1 10.1016/j.vaccine.2019.12.031 10.1016/j.ijid.2018.01.027 10.1016/j.jhep.2012.11.036 10.1186/s12887-017-0924-7 10.1016/j.vaccine.2011.07.098 10.1097/01.inf.0000176617.63457.9f 10.1086/503433 10.4161/hv.34393 10.1016/S0168-8278(03)00152-1 10.2471/BLT.17.205153 10.1097/00005176-200406002-00002 10.3389/fimmu.2018.01035 10.1080/21645515.2016.1250990 10.1002/hep.27406 10.1016/j.vaccine.2005.03.017 10.3201/eid2305.161477 10.1016/j.vaccine.2016.04.013 10.2165/00003495-200363100-00006 10.1016/j.jviromet.2015.11.016 10.1007/s12072-012-9354-7 10.1016/j.vaccine.2011.06.045 10.1093/cid/cir270 10.1016/j.vaccine.2015.05.070 10.1080/21645515.2017.1264795 10.1086/314578 10.1186/s12879-019-4134-9 10.1371/journal.pone.0219148 10.1111/hepr.12979 10.1016/j.vaccine.2009.01.027 10.1080/21645515.2016.1274475 10.1016/j.vaccine.2011.01.107 10.1016/S0140-6736(05)74663-8 |
| ContentType | Journal Article |
| Copyright | 2021 The Author(s). 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. Copyright Portland Press Ltd The Biochemical Society Sep 2021 2021 The Author(s). 2021 |
| Copyright_xml | – notice: 2021 The Author(s). – notice: 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: Copyright Portland Press Ltd The Biochemical Society Sep 2021 – notice: 2021 The Author(s). 2021 |
| DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7QL 7QO 7T7 7TK 7TM 7X7 7XB 88E 88I 8FD 8FE 8FH 8FI 8FJ 8FK 8G5 ABUWG AFKRA ATCPS AZQEC BBNVY BENPR BHPHI C1K CCPQU DWQXO FR3 FYUFA GHDGH GNUQQ GUQSH HCIFZ K9. LK8 M0S M1P M2O M2P M7N M7P MBDVC P64 PATMY PQEST PQQKQ PQUKI PYCSY Q9U RC3 7X8 5PM |
| DOI | 10.1042/BSR20210182 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Biotechnology Research Abstracts Industrial and Applied Microbiology Abstracts (Microbiology A) Neurosciences Abstracts Nucleic Acids Abstracts Health & Medical Complete (ProQuest Database) ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Science Database (Alumni Edition) Technology Research Database ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Research Library (Alumni Edition) ProQuest Central (Alumni) ProQuest Central UK/Ireland Agricultural & Environmental Science Collection ProQuest Central Essentials Biological Science Collection AUTh Library subscriptions: ProQuest Central ProQuest Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Central Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student Research Library Prep SciTech Premium Collection (Proquest) (PQ_SDU_P3) ProQuest Health & Medical Complete (Alumni) Biological Sciences Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Research Library (ProQuest Database) Science Journals (ProQuest Database) Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Research Library (Corporate) Biotechnology and BioEngineering Abstracts Environmental Science Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition Environmental Science Collection ProQuest Central Basic Genetics Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Research Library Prep ProQuest Central Student Technology Research Database ProQuest Central Essentials Nucleic Acids Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College Research Library (Alumni Edition) ProQuest Natural Science Collection Environmental Sciences and Pollution Management ProQuest Central Genetics Abstracts Health Research Premium Collection Biotechnology Research Abstracts Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Agricultural & Environmental Science Collection Biological Science Collection ProQuest Research Library Industrial and Applied Microbiology Abstracts (Microbiology A) ProQuest Medical Library (Alumni) ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Central Basic ProQuest Science Journals ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection Neurosciences Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Environmental Science Collection ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Environmental Science Database Engineering Research Database ProQuest One Academic ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | CrossRef MEDLINE MEDLINE - Academic Genetics Abstracts Research Library Prep |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Academic url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Chemistry Biology |
| EISSN | 1573-4935 |
| ExternalDocumentID | 10_1042_BSR20210182 34151935 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | China |
| GeographicLocations_xml | – name: China |
| GroupedDBID | --- -56 -5G -BR .86 0R~ 23N 4.4 5GY 5RE 5VS 6J9 78A 7X7 88E 88I 8FI 8FJ 8G5 AABGO AAHRG ABUWG ACGFS ACIWK ACPRK ADBBV ADIMF ADINQ AEGXH AENEX AFBBN AFKRA AFRAH AGIHE AHBYD ALMA_UNASSIGNED_HOLDINGS AOIJS ATCPS AZQEC BAWUL BBNVY BCNDV BENPR BGNMA BHPHI CCPQU CGR CS3 CUY CVF DIK DL5 DU5 DWQXO E3Z EBD EBS ECM EIF EMOBN EPAXT F5P FRP FYUFA GNUQQ GROUPED_DOAJ GUQSH GX1 H13 HCIFZ HMCUK HYE HZ~ I09 IZQ KDC KQ8 LAK M1P M2O M2P M48 M4Y M7P MV1 M~E NPM NU0 O9- OK1 PATMY PSQYO PYCSY QOK QOS R4E RHI RNS RPM RPO RPX RRX RSV SBL SDH SDM SOJ SV3 TR2 TSK U2A UKHRP VC2 ~EX AAYXX CITATION 3V. 7QL 7QO 7T7 7TK 7TM 7XB 8FD 8FE 8FH 8FK C1K FR3 K9. LK8 M7N MBDVC P64 PQEST PQQKQ PQUKI Q9U RC3 7X8 5PM |
| ID | FETCH-LOGICAL-c3881-ed71d24ed9f30ccacb91168863ec0a0e59afa7f501200cc0b18b8865bedf2eec3 |
| IEDL.DBID | RPM |
| ISSN | 0144-8463 |
| IngestDate | Tue Sep 17 20:47:32 EDT 2024 Fri Oct 25 12:20:41 EDT 2024 Thu Oct 10 22:59:56 EDT 2024 Thu Oct 10 18:00:35 EDT 2024 Fri Aug 23 01:17:11 EDT 2024 Wed Oct 16 00:42:18 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 9 |
| Keywords | anti-HBs Booster vaccination youths positive rates |
| Language | English |
| License | 2021 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c3881-ed71d24ed9f30ccacb91168863ec0a0e59afa7f501200cc0b18b8865bedf2eec3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0003-3912-2067 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8415346/ |
| PMID | 34151935 |
| PQID | 2937804337 |
| PQPubID | 2047900 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_8415346 proquest_miscellaneous_2543703969 proquest_journals_3033092356 proquest_journals_2937804337 crossref_primary_10_1042_BSR20210182 pubmed_primary_34151935 |
| PublicationCentury | 2000 |
| PublicationDate | 2021-09-30 |
| PublicationDateYYYYMMDD | 2021-09-30 |
| PublicationDate_xml | – month: 09 year: 2021 text: 2021-09-30 day: 30 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: New York |
| PublicationTitle | Bioscience reports |
| PublicationTitleAlternate | Biosci Rep |
| PublicationYear | 2021 |
| Publisher | Portland Press Ltd The Biochemical Society Portland Press Ltd |
| Publisher_xml | – name: Portland Press Ltd The Biochemical Society – name: Portland Press Ltd |
| References | Global Hepatitis Report 2017 (2021111620490468200_B3) 2017 Whitford (2021111620490468200_B1) 2018; 96 Romanò (2021111620490468200_B27) 2017; 13 Janssen (2021111620490468200_B37) 2015; 33 Shouval (2021111620490468200_B19) 2003; 39 Chang (2021111620490468200_B5) 2004; 39 Yoshida (2021111620490468200_B10) 2000; 355 Accrombessi (2021111620490468200_B23) 2020; 38 Lee (2021111620490468200_B30) 2017; 17 Zhu (2021111620490468200_B8) 2011; 29 Bandaru (2021111620490468200_B36) 2011; 29 FitzSimons (2021111620490468200_B31) 2005; 23 Wu (2021111620490468200_B18) 2018; 14 Cui (2021111620490468200_B6) 2017; 23 Leuridan (2021111620490468200_B16) 2011; 53 Liu (2021111620490468200_B35) 2017; 13 Lu (2021111620490468200_B21) 2017; 13 Weinberger (2021111620490468200_B25) 2018; 9 Zhang (2021111620490468200_B22) 2011; 29 van der Sande (2021111620490468200_B15) 2006; 193 Su (2021111620490468200_B12) 2007; 25 Su (2021111620490468200_B14) 2013; 58 Van Der Meeren (2021111620490468200_B7) 2016; 34 Jack (2021111620490468200_B11) 1999; 179 Seto (2021111620490468200_B34) 2013; 7 Wang (2021111620490468200_B17) 2017; 13 Obiri-Yeboah (2021111620490468200_B24) 2019; 14 Bagheri-Jamebozorgi (2021111620490468200_B26) 2014; 10 Yang (2021111620490468200_B32) 2016; 228 Zhao (2021111620490468200_B28) 2019; 19 Loubet (2021111620490468200_B2) 2020; 20 Dentinger (2021111620490468200_B9) 2005; 24 Ozeki (2021111620490468200_B33) 2018; 48 Keating (2021111620490468200_B20) 2003; 63 Wang (2021111620490468200_B4) 2014; 60 Kao (2021111620490468200_B13) 2009; 27 Zhu (2021111620490468200_B29) 2018; 71 |
| References_xml | – volume: 13 start-page: 903 year: 2017 ident: 2021111620490468200_B21 article-title: Effects of hepatitis B vaccine boosters on anti-HBs-negative children after primary immunization publication-title: Hum. Vaccin. Immunother. doi: 10.1080/21645515.2016.1260794 contributor: fullname: Lu – volume: 14 start-page: 1251 year: 2018 ident: 2021111620490468200_B18 article-title: The effects of booster vaccination of hepatitis B vaccine on children 5-15 years after primary immunization: a 5-year follow-up study publication-title: Hum. Vacc. Immunother. doi: 10.1080/21645515.2018.1426419 contributor: fullname: Wu – volume: 25 start-page: 8085 year: 2007 ident: 2021111620490468200_B12 article-title: Hepatitis B seroprevalence and anamnestic response amongst Taiwanese young adults with full vaccination in infancy, 20 years subsequent to national hepatitis B vaccination publication-title: Vaccine doi: 10.1016/j.vaccine.2007.09.013 contributor: fullname: Su – volume: 20 start-page: 7 year: 2020 ident: 2021111620490468200_B2 article-title: Alternative hepatitis B vaccine strategies in healthy non-responders to a first standard vaccination scheme publication-title: Lancet Infect. Dis. doi: 10.1016/S1473-3099(19)30582-1 contributor: fullname: Loubet – volume: 38 start-page: 1787 year: 2020 ident: 2021111620490468200_B23 article-title: Assessment of the anti-HBs antibody response in Beninese infants following 4 doses of HBV vaccine, including administration at birth, compared to the standard 3 doses regime; a cross-sectional survey publication-title: Vaccine doi: 10.1016/j.vaccine.2019.12.031 contributor: fullname: Accrombessi – volume: 71 start-page: 25 year: 2018 ident: 2021111620490468200_B29 article-title: Epidemiological serosurvey of hepatitis B virus among children aged 1-14 years in Guangdong Province, China publication-title: Int. J. Infect. Dis. doi: 10.1016/j.ijid.2018.01.027 contributor: fullname: Zhu – volume: 58 start-page: 684 year: 2013 ident: 2021111620490468200_B14 article-title: Efficacy of hepatitis B vaccine boosters among neonatally vaccinated university freshmen in Taiwan publication-title: J. Hepatol. doi: 10.1016/j.jhep.2012.11.036 contributor: fullname: Su – volume: 17 year: 2017 ident: 2021111620490468200_B30 article-title: Changes in hepatitis B virus antibody titers over time among children: a single center study from 2012 to 2015 in an urban of South Korea publication-title: BMC Pediatrics doi: 10.1186/s12887-017-0924-7 contributor: fullname: Lee – volume: 29 start-page: 7835 year: 2011 ident: 2021111620490468200_B8 article-title: Presence of immune memory and immunity to hepatitis B virus in adults after neonatal hepatitis B vaccination publication-title: Vaccine doi: 10.1016/j.vaccine.2011.07.098 contributor: fullname: Zhu – volume: 24 start-page: 786 year: 2005 ident: 2021111620490468200_B9 article-title: Persistence of antibody to hepatitis B and protection from disease among Alaska natives immunized at birth publication-title: J. Pediatr. Infect. Dis. Soc. doi: 10.1097/01.inf.0000176617.63457.9f contributor: fullname: Dentinger – volume: 193 start-page: 1528 year: 2006 ident: 2021111620490468200_B15 article-title: Long-term protection against carriage of hepatitis B virus after infant vaccination publication-title: J. Infect. Dis. doi: 10.1086/503433 contributor: fullname: van der Sande – volume: 10 start-page: 3731 year: 2014 ident: 2021111620490468200_B26 article-title: The persistence of anti-HBs antibody and anamnestic response 20 years after primary vaccination with recombinant hepatitis B vaccine at infancy publication-title: Hum. Vacc. Immunother. doi: 10.4161/hv.34393 contributor: fullname: Bagheri-Jamebozorgi – volume: 39 start-page: S70 year: 2003 ident: 2021111620490468200_B19 article-title: Hepatitis B vaccines publication-title: J. Hepatol. doi: 10.1016/S0168-8278(03)00152-1 contributor: fullname: Shouval – volume: 96 start-page: 484 year: 2018 ident: 2021111620490468200_B1 article-title: Long-term impact of infant immunization on hepatitis B prevalence: a systematic review and meta-analysis publication-title: Bull. World Health Organ. doi: 10.2471/BLT.17.205153 contributor: fullname: Whitford – volume: 39 start-page: S584 year: 2004 ident: 2021111620490468200_B5 article-title: Acute and chronic hepatitis: Working Group Report of the Second World Congress of Pediatric Gastroenterology, Hepatology, and Nutrition publication-title: J. Pediatr. Gastroenterol. Nutr. doi: 10.1097/00005176-200406002-00002 contributor: fullname: Chang – volume: 9 start-page: 1035 year: 2018 ident: 2021111620490468200_B25 article-title: Impaired immune response to primary but not to booster vaccination against hepatitis B in older adults publication-title: Front. Immunol doi: 10.3389/fimmu.2018.01035 contributor: fullname: Weinberger – volume: 13 start-page: 909 year: 2017 ident: 2021111620490468200_B17 article-title: Long-term persistence in protection and response to a hepatitis B vaccine booster among adolescents immunized in infancy in the western region of China publication-title: Hum. Vacc. Immunother. doi: 10.1080/21645515.2016.1250990 contributor: fullname: Wang – volume: 60 start-page: 2099 year: 2014 ident: 2021111620490468200_B4 article-title: The global burden of liver disease: the major impact of China publication-title: Hepatology doi: 10.1002/hep.27406 contributor: fullname: Wang – volume: 23 start-page: 4158 year: 2005 ident: 2021111620490468200_B31 article-title: Long-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutants publication-title: Vaccine doi: 10.1016/j.vaccine.2005.03.017 contributor: fullname: FitzSimons – volume: 23 start-page: 765 year: 2017 ident: 2021111620490468200_B6 article-title: Prevention of chronic hepatitis B after 3 decades of escalating vaccination policy, China publication-title: Emerg. Infect. Dis. doi: 10.3201/eid2305.161477 contributor: fullname: Cui – volume: 34 start-page: 2745 year: 2016 ident: 2021111620490468200_B7 article-title: Immunity to hepatitis B persists in adolescents 15-16 years of age vaccinated in infancy with three doses of hepatitis B vaccine publication-title: Vaccine doi: 10.1016/j.vaccine.2016.04.013 contributor: fullname: Van Der Meeren – volume: 63 start-page: 1021 year: 2003 ident: 2021111620490468200_B20 article-title: Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogenicity and protective efficacy against hepatitis B publication-title: Drugs doi: 10.2165/00003495-200363100-00006 contributor: fullname: Keating – year: 2017 ident: 2021111620490468200_B3 article-title: World Health Organization contributor: fullname: Global Hepatitis Report 2017 – volume: 228 start-page: 39 year: 2016 ident: 2021111620490468200_B32 article-title: The Lumipulse G HBsAg-Quant assay for screening and quantification of the hepatitis B surface antigen publication-title: J. Virol. Methods doi: 10.1016/j.jviromet.2015.11.016 contributor: fullname: Yang – volume: 7 start-page: 98 year: 2013 ident: 2021111620490468200_B34 article-title: Evidence of serologic activity in chronic hepatitis B after surface antigen (HBsAg) seroclearance documented by conventional HBsAg assay publication-title: Hepatol. Int. doi: 10.1007/s12072-012-9354-7 contributor: fullname: Seto – volume: 29 start-page: 6276 year: 2011 ident: 2021111620490468200_B22 article-title: Surface antibody and cytokine response to recombinant Chinese hamster ovary cell (CHO) hepatitis B vaccine publication-title: Vaccine doi: 10.1016/j.vaccine.2011.06.045 contributor: fullname: Zhang – volume: 53 start-page: 68 year: 2011 ident: 2021111620490468200_B16 article-title: Hepatitis B and the need for a booster dose publication-title: Clin. Infect. Dis. doi: 10.1093/cid/cir270 contributor: fullname: Leuridan – volume: 33 start-page: 3614 year: 2015 ident: 2021111620490468200_B37 article-title: Immunogenicity of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in subpopulations of healthy adults 18–70 years of age publication-title: Vaccine doi: 10.1016/j.vaccine.2015.05.070 contributor: fullname: Janssen – volume: 13 start-page: 981 year: 2017 ident: 2021111620490468200_B27 article-title: Persistence of immunity 18–19 years after vaccination against hepatitis B in 2 cohorts of vaccinees primed as infants or as adolescents in Italy publication-title: Hum. Vacc. Immunother. doi: 10.1080/21645515.2017.1264795 contributor: fullname: Romanò – volume: 179 start-page: 489 year: 1999 ident: 2021111620490468200_B11 article-title: What level of hepatitis B antibody is protective? publication-title: J. Infect. Dis. doi: 10.1086/314578 contributor: fullname: Jack – volume: 19 start-page: 482 year: 2019 ident: 2021111620490468200_B28 article-title: Immune persistence 17 to 20 years after primary vaccination with recombination hepatitis B vaccine (CHO) and the effect of booster dose vaccination publication-title: BMC Infect. Dis. doi: 10.1186/s12879-019-4134-9 contributor: fullname: Zhao – volume: 14 start-page: e0219148 year: 2019 ident: 2021111620490468200_B24 article-title: Post Hepatitis B vaccination sero-conversion among health care workers in the Cape Coast Metropolis of Ghana publication-title: PLoS ONE doi: 10.1371/journal.pone.0219148 contributor: fullname: Obiri-Yeboah – volume: 48 start-page: E263 year: 2018 ident: 2021111620490468200_B33 article-title: Analysis of hepatitis B surface antigen (HBsAg) using high-sensitivity HBsAg assays in hepatitis B virus carriers in whom HBsAg seroclearance was confirmed by conventional assays publication-title: Hepatol. Res. doi: 10.1111/hepr.12979 contributor: fullname: Ozeki – volume: 27 start-page: 1858 year: 2009 ident: 2021111620490468200_B13 article-title: Long-term efficacy of plasma-derived and recombinant hepatitis B vaccines in a rural township of Central Taiwan publication-title: Vaccine doi: 10.1016/j.vaccine.2009.01.027 contributor: fullname: Kao – volume: 13 start-page: 1014 year: 2017 ident: 2021111620490468200_B35 article-title: Influences of obesity on the immunogenicity of Hepatitis B vaccine publication-title: Hum. Vacc. Immunother. doi: 10.1080/21645515.2016.1274475 contributor: fullname: Liu – volume: 29 start-page: 3038 year: 2011 ident: 2021111620490468200_B36 article-title: Altered or impaired immune response upon vaccination in WNIN/Ob rats publication-title: Vaccine doi: 10.1016/j.vaccine.2011.01.107 contributor: fullname: Bandaru – volume: 355 start-page: 1464 year: 2000 ident: 2021111620490468200_B10 article-title: Hepatitis B booster vaccination for healthcare workers publication-title: Lancet doi: 10.1016/S0140-6736(05)74663-8 contributor: fullname: Yoshida |
| SSID | ssj0004934 |
| Score | 2.3439963 |
| Snippet | Hepatitis B virus (HBV) infection is still a public issue in the world. Hepatitis B vaccination is widely used as an effective measure to prevent HBV... Abstract Background: Hepatitis B virus (HBV) infection is still a public issue in the world. Hepatitis B vaccination is widely used as an effective measure to... Background: Hepatitis B virus (HBV) infection is still a public issue in the world. Hepatitis B vaccination is widely used as an effective measure to prevent... BACKGROUNDHepatitis B virus (HBV) infection is still a public issue in the world. Hepatitis B vaccination is widely used as an effective measure to prevent HBV... Background: Hepatitis B virus (HBV) infection is still a public issue in the world. Hepatitis B vaccination is widely used as an effective measure to prevent... |
| SourceID | pubmedcentral proquest crossref pubmed |
| SourceType | Open Access Repository Aggregation Database Index Database |
| StartPage | 1 |
| SubjectTerms | Adolescent Age Factors Age groups Antibodies Biomarkers - blood Child Child, Preschool Family medical history Female Females Follow-Up Studies Gastrointestinal, Renal & Hepatic Systems Gender Hepatitis Hepatitis B Hepatitis B - immunology Hepatitis B - prevention & control Hepatitis B - virology Hepatitis B Antibodies - blood Hepatitis B Surface Antigens - immunology Hepatitis B Vaccines - administration & dosage Hepatitis B virus - drug effects Hepatitis B virus - immunology Humans Immunization Immunization, Secondary Immunology & Inflammation Infant Infections Laboratories Maintenance Male Medical research Statistical analysis Time Factors Treatment Outcome Vaccines Vaccines, Synthetic - administration & dosage Virology |
| SummonAdditionalLinks | – databaseName: AUTh Library subscriptions: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9RAEF_0iuiLaP2KtjJCX5dms5tk40vplZYiWKRa6FvY7AcNlORs7ir36H_uTJK79lT6PEnY7MzOzM7Hbxjbk5nIvFSGS689Rass1044LqRJhA1JIfr2sa9n2emF-nKZXo4Bt24sq1zpxF5Ru9ZSjHwfzRJh5UiZH8x-cpoaRdnVcYTGY7aV4E0hnrCt6fHZt_O7zshCDujeSnG0tHLs0ENJ3Z9-P0_owiN0smmT_nE0_66XvGeATl6w56PnCIcDq1-yR77ZZk-GWZLLbfb0aDW67RX7jcyHoRzr1gOBQXTQBrjyVD49rzuYQre4CcZ6wI2tq9YtoW5gSeP0oJ8aDuh8E4QC3Bpr6yFi-BkMKL7EowEBpaf9xRcz6OFpgaK5cE1F5dAZwht-zS5Ojn8cnfJx1gK3UmvBvcuFS5R3RZAxctVWqAUzrTPpbWxinxYmmDyk1GuL9LgSukJqWnkXEu-tfMMmTdv4dwyKYDx1ZuJFRqtUWJ3mQcfB53kljHUuYnur3S5nA6RG2afCVVLeY0rEdlacKMdz1ZV3UvBfMtpjGaPLmmYR-7Qm4-ZTFsQ0vl3gJ1IlUc0VWRGxtwNf18tAk04ebRqxfIPj6wcIjHuT0tRXPSi3xlelyt4_vOoP7Bn931BwssMm85uF30WvZl59HEX3D3Y9-M4 priority: 102 providerName: ProQuest – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fb9QwDLbGELAXBONXYSAj7bXQNGmbIiHEJqYJCR6Ak_ZWpamjVZracb0b9JH_HKe9nu7Gnnh2U7WxE39O7M8AhzIVKUllQkma_GmVDXUlqlBIEwvr4lwM5WNfvqanM_X5LDnbgakZ52oCuxtDO99Paja_ePP7Z_-BF_z78YYyfnv0_VvsQxeGyrfgdqw4RPc5fGqDNjyXI8m3UiE7XLkq1Ls2eA_u8p7uIU2y7aX-gZ7XMyg3XNLJA7i_wpL4cVT-Q9ihZh_ujN0l-324dzw1c3sEf9gccEzQuiL09BAdtg7PySdUL-oOj7Bbzp2xhDzVddlWPdYN9r7BHg59xJHhuCdVwCtjbT2eIb5DgyrsebGgY3tqf4XLSxwIa9Gf7-KFTzPHzngG4scwO_n04_g0XHVfCK3UWoRUZaKKFVW5kxHr2Za8L6Zap5JsZCJKcuNM5hJffcvyqBS6ZGlSUuViIiufwG7TNvQMMHeGfK0mhzZaJcLqJHM6cpRlpTC2qgI4nGa7uBxJNorhclzFxYZ-AjiYNFFMhlIwXPEcSlJmN4rZQ8uIQWySBvB6LebJ9_cipqF2ya9IlOSNL0_zAJ6Oel1_xmQQAWRbGl8_4Om5tyVNfT7QdGseKlX6_L9HvoA9_-tjdsoB7C7mS3rJEGhRvhrM-y9gWQaU priority: 102 providerName: Scholars Portal |
| Title | The positive rates of hepatitis B surface antibody in youth after booster vaccination: a 4-year follow-up study with large sample |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/34151935 https://www.proquest.com/docview/2937804337 https://www.proquest.com/docview/3033092356 https://search.proquest.com/docview/2543703969 https://pubmed.ncbi.nlm.nih.gov/PMC8415346 |
| Volume | 41 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Na9wwEB2SlLa5lDb9cpsuU8jVWduSbLm37pIQChtC2sDejCxLxJDYS7ybsMf88478sWTbnno0YxtbM9Y8yW_eAByxOIwN48pnRhq3W6V9WYSFHzIVhdpGadiWj83O47Mr_mMu5jsghlqYlrSv8_K4urk9rsrrllu5uNXjgSc2vphNJWUdxuPxLuxSgA5L9KEYMmWdoDfnPiVX1hflUXCOJz8vI7fGIUy9Dy9o_nbwRWxnpL9g5p9sySfp5_Q1vOpxI37vnu8N7JjqAJ53nSTXB_ByOjRuewuP5HrsyFj3Bp0URIO1xWvjyNPLssEJNqs7q7RBGtYyr4s1lhWuXTM9bHuGI0FvJ6CA90rrstsv_IYKub-mDwMtxU794K8W2IrTotvLxRtHKcdGObXhd3B1evJreub3nRZ8zaQMfVMkYRFxU6SWBeRTndMcGEsZM6MDFRiRKqsSK1ylLdmDPJQ5WUVuChsZo9l72KvqynwETK0yri6TljGSi1BLkVgZWJMkeah0UXhwNIx2tugENbL2RziPsif-8eBw8ETWf1VNRtDE6SUxlvzTTNmYBQRYRezB142ZBt_9A1GVqVd0C8EZTXJpnHrwofPr5jGGgPAg2fL45gQnxb1toQhtJbn7iPz031d-hn336h0T5RD2lncr84XgzjIfUZDPkxE8m5ycX1zS0YzLURvyvwEO0QPG |
| link.rule.ids | 230,315,730,783,787,888,2228,12068,21400,24330,27936,27937,31731,31732,33756,33757,43322,43817,53804,53806 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dT9RAEN8oxMCLUVSsoo4Jrw3d7rbd-mI8AjkVLgYh4a3Z7kdoYtqD3mHu0f_cmbZ3cGp8nrbZ7szOzM7HbxjbFylPnZA6FE45ilaZUFluQy50zI2Pc961j51O0vGF_HKZXA4Bt3Yoq1zqxE5R28ZQjPwAzRJh5QiRfZxehzQ1irKrwwiNh2yToKrw8rU5Opp8O7vrjMxFj-4tZYiWVgwdeiipB6PvZzFdeLiK123SX47mn_WS9wzQ8RP2ePAc4VPP6qfsgat32KN-luRih20dLke3PWO_kPnQl2PdOiAwiBYaD1eOyqdnVQsjaOc3XhsHuLFV2dgFVDUsaJwedFPDAZ1vglCAW21M1UcMP4AGGS7waIBH6Wl-hvMpdPC0QNFc-EFF5dBqwht-zi6Oj84Px-EwayE0QikeOptxG0tncy8i5KopUQumSqXCmUhHLsm115lPqNcW6VHJVYnUpHTWx84Z8YJt1E3tXjLIvXbUmYkXGSUTblSSeRV5l2Ul18bagO0vd7uY9pAaRZcKl3FxjykB21tyohjOVVvcScE_yWiPRYQua5IG7P2KjJtPWRBdu2aOn0ikQDWXp3nAdnu-rpaBJp082iRg2RrHVw8QGPc6pa6uOlBuha8Kmb76_6rfsa3x-elJcfJ58vU126Z_7YtP9tjG7Gbu3qCHMyvfDmL8G2zu-8g |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB5BEaUXHqVAoMAg9ZpNHOfhcKMLq_JoVQGVKi6R49hqRJusmt2i5cY_Z5zHardw6nmcyIk_e8b2N98A7PGYxZqH0uVaaHtapVxRsMJlXAZMmSBlbfrY4VF8cBJ-Oo1OV0p9taR9lZej6vxiVJVnLbdyeqG8gSfmHR-OBXkdHsbetDDebbhDc9aPh436kBKZ8k7WOwxdcrG8T80jiHr7374GdqdDkfUWbNIqboOYaN0v_RNsXudMrjihyQP4MXS_4578HM1n-Uj9vqbseKPvewj3-9AU33VNHsEtXW3D3a5Y5WIb7o2H2nCP4Q-hCzu-15VGqzbRYG3wTFt-9qxscB-b-aWRSiONXJnXxQLLChe2Xh-2ZcmRonur0YBXUqmyO5J8ixJDd0FzDw3Bs_7lzqfY6t-iPS7Gc8tax0ZaQeMdOJl8-D4-cPtiDq7iQjBXFwkrglAXqeE-wUbltMzGQsRcK1_6OkqlkYmJbDIv2f2ciZysUa4LE2it-BPYqOpKPwNMjdQ29ZN2SiKMmBJRYoRvdJLkTKqicGBvGMps2ml2ZO1dexhkK4PvwO4wzFk_cZuMoh8rycR58l8zOXzuU0wcxQ68WZrp59trFlnpek6viEJO62gapw487UCz7MaANgeSNTgtG1i173ULgaRV_e5B8fzGT76GzeP3k-zLx6PPL2DL_oWO97ILG7PLuX5JwdUsf9VOo7_TxyTg |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+positive+rates+of+hepatitis+B+surface+antibody+in+youth+after+booster+vaccination%3A+a+4-year+follow-up+study+with+large+sample&rft.jtitle=Bioscience+reports&rft.au=Zhu%2C+Xia&rft.au=Wang%2C+Juan&rft.au=Wang%2C+Ming&rft.au=Du%2C+Ling-yao&rft.date=2021-09-30&rft.pub=Portland+Press+Ltd&rft.issn=0144-8463&rft.eissn=1573-4935&rft.volume=41&rft.issue=9&rft_id=info:doi/10.1042%2FBSR20210182&rft_id=info%3Apmid%2F34151935&rft.externalDBID=PMC8415346 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0144-8463&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0144-8463&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0144-8463&client=summon |